

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: Unassigned

Syed F.A. Hossainy et al.

Serial No. 10/668,781

Art Unit: 3731

Filed: September 22, 2003

Title: Composite Stent with Regioselective Material and Method of Forming the Same

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents, unpublished patent applications and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: March 31, 2004


SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,



Paul M. Meyer, Jr.
Attorney for Applicants
Reg. No. 47,791

Please type a plus sign (+) inside this box →



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/668,781	
	Filing Date	September 22, 2003	
	First Named Inventor	Syed F.A. Hossainy	
	Group Art Unit	3731	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission (excluding references)	12	Attorney Docket No.	50623.333

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Deposit Account Authorization 07-1850	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Postage Paid Return Postcard	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Response to Office Action	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Submission of Formal Drawings (in duplicate)
<input type="checkbox"/> Petition for Extension of Time (___ month) (in duplicate)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Amendment Transmittal Letter (in duplicate)	<input type="checkbox"/> Terminal Disclaimer	20 Foreign Patent Documents;
<input checked="" type="checkbox"/> Information Disclosure Statement with Form PTO-1449 citing 192 References	<input type="checkbox"/> Request for Refund	18 Other Documents;
<input type="checkbox"/> Request for Continued Examination (RCE) Transmittal	<input type="checkbox"/> CD, Number of CD(s) _____	2 Unpublished Patent Applications
<input type="checkbox"/> Express Mail Label No.	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Paul J. Meyer, Jr., Reg. No. 47,791
Signature	
Date	March 31, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:			
Typed or printed name	Dilora Haddad		
Signature		Date	March 31, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.333		Application No. 10/668,781	
INFORMATION DISCLOSURE CITATION in an Application				Applicant Syed F.A. Hossainy et al.			
(Use several sheets if necessary)				Filing Date September 22, 2003		Group Art Unit 3731	
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,733,665	3/29/88	Palmaz	128	343	
	A2	4,800,882	1/31/89	Gianturco	128	343	
	A3	4,886,062	12/12/89	Wiktor	128	343	
	A4	4,931,287	6/5/90	Bae et al.	424	484	
	A5	4,977,901	12/18/90	Ofstead	128	772	
	A6	4,994,560	2/19/91	Kruper, Jr. et al.	534	10	
	A7	5,040,548	8/20/91	Yock	128	898	
	A8	5,059,166	10/22/91	Fischell	600	3	
	A9	5,064,435	11/12/91	Porter	623	12	
	A10	5,087,244	2/11/92	Wolinsky	604	53	
	A11	5,100,429	3/31/92	Sinofsky et al.	606	195	
	A12	5,213,561	5/25/93	Weinstein et al.	600	7	
	A13	5,229,172	7/20/93	Cahalan et al.	427	536	
	A14	5,232,444	8/3/93	Just	604	96	
	A15	5,258,419	11/2/93	Rolando et al.	522	109	
	A16	5,278,200	1/11/94	Coury et al.	523	112	
	A17	5,308,641	5/3/94	Cahalan et al.	427	2	
	A18	5,328,471	7/12/94	Slepian	604	101	
	A19	5,336,518	8/9/94	Narayanan et al.	623	1	
	A20	5,342,283	8/30/94	Good	600	8	
	A21	5,342,621	8/30/94	Eury	424	423	
	A22	5,344,455	9/6/94	Keogh et al.	623	11	
	A23	5,350,800	9/27/94	Verhoeven et al.	525	54.2	
	A24	5,366,504	11/22/94	Andersen et al.	623	11	
	A25	5,411,466	5/2/95	Hess	600	3	
	A26	5,415,938	5/16/95	Cahalan et al.	428	409	
	A27	5,429,618	7/4/95	Keogh	604	266	

	A28	5,443,496	8/22/95	Schwartz et al.	623	1	
	A29	5,464,450	11/7/95	Buscemi et al.	623	6	
	A30	5,464,650	11/7/95	Berg et al.	427	2.30	
	A31	5,470,313	11/28/95	Crocker	604	96	
	A32	5,476,509	12/19/95	Keogh et al.	623	1	
	A33	5,500,013	3/19/96	Buscemi et al.	623	1	
	A34	5,551,954	9/3/96	Buscemi et al.	623	1	
	A35	5,554,182	9/10/96	Dinh et al.	623	1	
	A36	5,571,166	11/5/96	Dinh et al.	623	1	
	A37	5,578,073	11/26/96	Haimovich et al.	623	1	
	A38	5,591,224	1/7/97	Schwartz et al.	623	1	
	A39	5,591,227	1/7/97	Dinh et al.	623	1	
	A40	5,599,352	2/4/97	Dinh et al.	623	1	
	A41	5,605,696	2/25/97	Eury et al.	424	423	
	A42	5,624,411	4/29/97	Tuch	604	265	
	A43	5,628,730	5/13/97	Shapland et al.	604	21	
	A44	5,628,785	5/13/97	Schwartz et al.	623	1	
	A45	5,637,113	6/10/97	Tartaglia et al.	623	1	
	A46	5,649,951	7/22/97	Davidson	606	198	
	A47	5,649,977	7/22/97	Campbell	623	1	
	A48	5,667,767	9/16/97	Greff et al.	424	9.411	
	A49	5,670,558	9/23/97	Onishi et al.	523	112	
	A50	5,674,242	10/7/97	Phan et al.	606	198	
	A51	5,693,085	12/2/97	Buirge et al.	623	1	
	A52	5,693,376	12/2/97	Fetherston et al.	427	523	
	A53	5,697,967	12/16/97	Dinh et al.	623	1	
	A54	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A55	5,702,818	12/30/97	Cahalan et al.	428	409	
	A56	5,707,385	1/13/98	Williams	606	192	
	A57	5,711,812	1/27/98	Chapek et al.	118	723 E	
	A58	5,713,949	2/3/98	Jayaraman	623	1	
	A59	5,716,981	2/10/98	Hunter et al.	514	449	
	A60	5,722,984	3/3/98	Fischell et al.	606	198	

	A61	5,730,698	3/24/98	Fischell et al.	600	3	5/9/95
	A62	5,766,710	6/16/98	Turnlund et al.	428	36.1	
	A63	5,769,883	6/23/98	Buscemi et al.	623	1	
	A64	5,769,884	6/23/98	Solovay	623	1	
	A65	5,782,742	7/21/98	Crocker	600	3	
	A66	5,800,392	9/1/98	Racchini	604	96	
	A67	5,811,151	9/22/98	Hendriks et al.	427	2.24	
	A68	5,824,048	10/20/98	Tuch	623	1	
	A69	5,824,049	10/20/98	Ragheb et al.	623	1	
	A70	5,826,586	10/27/98	Mishra et al.	128	898	
	A71	5,830,178	11/3/98	Jones et al.	604	49	
	A72	5,837,313	11/17/98	Ding et al.	427	2.21	
	A73	5,840,009	11/24/98	Fischell et al.	600	3	
	A74	5,843,172	12/1/98	Yan	623	1	
	A75	5,851,508	12/22/98	Greff et al.	424	9.411	
	A76	5,857,998	1/12/99	Barry	604	96	
	A77	5,858,556	1/12/99	Eckhart et al.	428	586	
	A78	5,858,990	1/12/99	Walsh	514	44	
	A79	5,865,814	2/2/99	Tuch	604	265	
	A80	5,866,113	2/2/99	Hendriks et al.	424	78.17	
	A81	5,871,436	2/16/99	Eury	600	3	
	A82	5,871,437	2/16/99	Alt	600	3	
	A83	5,873,904	2/23/99	Ragheb et al.	623	1	
	A84	5,893,840	4/13/99	Hull et al.	604	96	
	A85	5,897,911	4/27/99	Loeffler	427	2.25	
	A86	5,898,178	4/27/99	Bunker	250	423	
	A87	5,902,631	5/11/99	Wang et al.	427	2.1	
	A88	5,916,234	6/29/99	Lam	606	198	
	A89	5,925,552	7/20/99	Keogh et al.	435	174	
	A90	5,928,916	7/27/99	Keogh	435	174	
	A91	5,951,881	09/14/99	Rogers et al.	216	41	
	A92	5,968,091	10/19/99	Pinchuk et al.	623	1	
	A93	5,968,092	10/19/99	Buscemi et al.	623	1	

	A94	5,971,954	10/26/99	Conway et al.	604	96	
	A95	5,972,027	10/26/99	Johnson	623	1	
	A96	5,972,029	10/26/99	Fuisz	623	1	
	A97	5,980,564	11/9/99	Stinson	623	1	
	A98	5,980,564	11/9/00	Stinson	623	1	
	A99	5,980,928	11/9/99	Terry	424	427	
	A100	5,980,972	11/9/99	Ding	427	2.24	
	A101	5,997,517	12/7/99	Whitbourne	604	265	
	A102	6,010,530	1/4/00	Goicoechea	623	1	
	A103	6,013,099	1/11/00	Dinh et al.	623	1	
	A104	6,015,541	1/18/00	Greff et al.	424	1.25	
	A105	6,019,789	2/1/00	Dinh et al.	623	1	
	A106	6,024,918	2/15/00	Hendriks et al.	422	44	
	A107	6,027,526	2/22/00	Limon et al.	623	1	
	A108	6,033,719	3/7/00	Keogh	427	2.12	
	A109	6,042,606	3/28/00	Frantzen	623	1	
	A110	6,042,875	3/28/00	Ding et al.	427	2.24	
	A111	6,059,752	5/9/00	Segal	604	107	
	A112	6,071,305	6/6/00	Brown et al.	623	1	
	A113	6,080,099	6/27/00	Slater	600	8	
	A114	6,080,190	6/27/00	Schwartz	623	1	
	A115	6,093,199	6/25/00	Brown et al.	606	200	
	A116	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A117	6,099,455	8/8/00	Columbo et al.	600	3	11/25/98
	A118	6,099,559	8/8/00	Nolting	623	1.16	5/28/98
	A119	6,099,561	8/8/00	Alt	623	1.44	10/20/98
	A120	6,106,454	8/22/00	Berg et al.	600	3	6/17/97
	A121	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A122	6,140,127	10/31/00	Sprague	435	395	2/18/98
	A123	6,140,431	10/31/00	Kinker et al.	526	79	2/12/98
	A124	6,149,574	11/21/00	Trauthen et al.	600	3	3/17/98
	A125	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A126	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99

	A127	6,168,619	1/2/01	Dinh et al.	623	1.13	10/16/98
	A128	6,203,551	3/20/01	Wu	606	108	10/4/99
	A129	6,214,901	4/10/01	Chudzik et al.	523	113	4/15/99
	A130	6,224,894	5/1/01	Jamiolkowski et al.	424	426	8/11/00
	A131	6,231,590	5/15/01	Slaikeu et al.	606	200	7/12/99
	A132	6,242,041	6/5/01	Katoot et al.	427	2.24	11/10/98
	A133	6,253,443	7/3/01	Johnson	29	557	10/18/99
	A134	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A135	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A136	6,262,034	7/17/01	Mathiowitz et al.	514	44	11/25/97
	A137	6,273,850	8/14/01	Gambale	600	3	10/29/97
	A138	6,273,913	8/14/01	Wright et al.	623	1.42	4/16/98
	A139	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A140	6,296,603	10/2/01	Turnlund et al.	600	3	5/26/98
	A141	6,319,520	11/20/01	Wuthrich et al.	424	482	6/27/00
	A142	6,344,035	2/5/02	Chudzik et al.	604	265	10/20/00
	A143	6,379,379	4/30/02	Wang	623	1.31	8/13/99
	A144	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A145	6,413,272	7/2/02	Igaki	623	1.15	2/28/01
	A146	6,488,701	12/3/02	Nolting et al.	623	1.13	3/31/98
	A147	6,504,307	1/7/03	Malik et al.	315	111.21	11/30/00
	A148	6,524,232	2/25/03	Tang et al.	600	3	12/22/00
	A149	6,554,758	4/29/03	Turnlund et al.	600	3	1/5/01
	A150	6,582,417	6/24/03	Ledesma et al.	604	529	2/16/00
	A151	6,605,114	8/12/03	Yan et al.	623	1.43	10/29/99
	A152	09/697,106		Hossainy et al.			10/26/00
	A153	09/834,012		Hossainy et al.			4/12/01
	A154	2001/0001806	5/24/01	Turnlund et al.	600	3	1/5/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 90/01969	3/8/90	PCT				
	B2	WO91/12846	9/5/91	PCT				
	B3	EP 0 627 226	12/7/94	European				

	B4	EP 0665023	8/2/95	European			
	B5	EP 0 701 803	3/20/96	European			
	B6	WO97/45105	12/4/97	PCT			
	B7	WO 98/23228	6/4/98	PCT			
	B8	EP 0 850 604	7/1/98	European			
	B9	19916086	10/14/99	DE			X
	B10	WO99/63981	12/16/99	PCT			
	B11	EP 0970711	1/12/00	European			
	B12	EP 0 972 498	1/19/00	European			
	B13	WO00/12147	3/9/00	PCT			
	B14	EP 0 850 651	6/28/00	European			
	B15	WO00/64506	11/2/00	PCT			
	B16	WO01/01890	1/11/01	PCT			
	B17	EP 1 103 234	5/30/01	European			X
	B18	WO01/45763	6/28/01	PCT			
	B19	WO 01/91918	12/6/01	PCT			
	B20	WO 02/47731	6/20/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2):252A (1989) (Abstract).
	C2	Fischell et al., <i>Low-Dose, β-Particle Emission from 'Stent' Wire Results in Complete, Localized Inhibition of Smooth Muscle Cell Proliferation</i> , Circulation, Vol. 90(6):2956-2963, December 1994.
	C3	Hehrlein et al., <i>Low-Dose Radioactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits</i> , Circulation, Vol. 92(6):1570-1575, September 15, 1995.
	C4	Liermann et al., <i>Prophylactic Endovascular Radiotherapy to Prevent Intimal Hyperplasia after Stent Implantation in Femoropopliteal Arteries</i> , CardioVascular and Interventional Radiology 17:12-16, 1994.
	C5	Malik et al., <i>Development of an Energetic Ion Assisted Mixing and Deposition Process for TiN_x and Diamondlike Carbon Films, Using a Co-axial Geometry in Plasma Source Ion Implantation</i> , J. Vac. Sci. Technol. A 15(6):2875-2879 (Nov./Dec. 1997).
	C6	Malik et al., <i>Overview of Plasma Source Ion Implantation Research at University of Wisconsin-Madison</i> , J. Vac. Sci. Technol. B 12(2):843-849 (Mar./Apr. 1994).
	C7	Malik et al., <i>Sheath Dynamics and Dose Analysis for Planar Targets in Plasma Source Ion Implantation</i> , Plasma Sources Sci. Technol. 2:81-85 (1993).
	C8	Matsumaru et al., <i>Embolic Materials for Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn. 8(7):555-569 (1997).
	C9	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6):2490-2498 (1985).
	C10	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).

	C11	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , Am. Heart J. 136(6):1081-1087 (Dec. 1998).
	C12	Scheuer et al., <i>Model of Plasma Source Ion Implantation in Planar, Cylindrical, and Spherical Geometries</i> , J. Appl. Phys. 67(3):1241-1245 (Feb. 1990).
	C13	Serruys et al., <i>I Like the Candy, I Hate the Wrapper; the ³²P Radioactive Stent</i> , Circulation 101:3-7 (Jan. 2000).
	C14	Shamim et al., <i>Measurement of Electron Emission Due to Energetic Ion Bombardment in Plasma Source Ion Implantation</i> , J. Appl. Phys. 70(9):4756-4759 (Nov. 1991).
	C15	Shamim et al., <i>Measurements of Spatial and Temporal Sheath Evolution for Spherical and Cylindrical Geometries in Plasma Source Ion Implantation</i> , J. Appl. Phys. 69(5):2904-2908 (March 1991).
	C16	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chem. Abstracts 125:212307 (1996).
	C17	van der Giessen et al., <i>"Edge Effect" of ³²P Radioactive Stents is Caused by the Combination of Chronic Stent Injury and Radioactive Dose Falloff</i> , Circ. 104:2236-2241 (Oct. 30, 2001).
	C18	Wiesendanger et al., <i>Contributions Of Scanning Probe Microscopy And Spectroscopy To The Investigation And Fabrication Of Nanometer-Scale Structures</i> , J. Vac. Sci. Technol. B, 12(2):515-529 (Mar./Apr. 1994).
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		